"Do Not Use Weight-Loss Injections Without Caution": MFDS Issues Warning

The Ministry of Food and Drug Safety (MFDS) has urged the public to use GLP-1 class obesity treatments, such as Wegovy, with caution and strictly according to the prescribed usage and dosage.
GLP-1 class obesity treatments are prescription drugs indicated for adult patients with an initial Body Mass Index (BMI) of 30 kg/m² or higher, or for overweight adults with a BMI between 27 kg/m² and 30 kg/m² who have at least one weight-related comorbidity, such as hypertension.
The MFDS particularly emphasized regarding adolescents that "as they are in a stage where growth is not yet complete, caution must be exercised regarding nutritional deficiencies and weight loss."
The ministry requested that these products not be traded between individuals or purchased through overseas direct shipping, as they are prescription drugs that must be used under a doctor's prescription and a pharmacist's guidance.
The MFDS stressed, "Products purchased through overseas direct shipping have unverified manufacturing and distribution processes, posing risks of counterfeit or substandard drugs. Even if harm occurs during use, it is difficult to receive legal protection, such as product recalls or compensation."
(Photo: Courtesy of Yonhap News TV, Yonhap News)
※ Please note: This article was translated by AI and may contain errors.